Navigation Links
HYALGAN® (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici S.p.A.
Date:9/15/2011

PARSIPPANY, N.J., Sept. 15, 2011 /PRNewswire/ -- Fidia Farmaceutici S.p.A. (Fidia) announced today that commercial rights for HYALGAN ® (sodium hyaluronate), an injectable treatment for knee pain caused by osteoarthritis when simple painkillers or exercise and physical therapy are not enough, will be transferred from Sanofi US LLC back to Fidia on September 24, 2011.  Fidia Farmaceutici S.p.A. is the owner and manufacturer of HYALGAN. After September 24th, Fidia will promote, distribute and sell HYALGAN in the United States through its wholly owned subsidiary, Fidia Pharma USA Inc, headquartered in Parsippany, N.J.

The company stated that the transfer of US commercial responsibility for HYALGAN will not result in any change to the product. Current volume purchase agreements will continue to be honored and the product's current J-code will remain unchanged.  Critical services such as the HYALGAN® patient assistance program will also remain unchanged and can be accessed at 1-866-7-HYALGAN. Until September 24th, medical professionals can direct their questions about HYALGAN to their Sanofi US LLC sales representative.

HYALGAN was approved for marketing by the U.S. Food and Drug Administration in 1997.  More than 38 million doses of HYALGAN® have been administered worldwide since its introduction.(1)

About Fidia Farmaceutici S.p.A

Headquartered in Abano Terme, Northeast Italy, Fidia Farmaceutici S.p.A., has over 50 years of successful R&D and industry experience with biologically active molecules.  As a model for international success, Fidia has focused its core business activities on hyaluronic acid, developing and providing a wide range of products for various specialties. Fidia holds more than 960 patents on hyaluronic acid and its applications and its products are currently in over 70 countries worldwide.  Fidia's most important proprietary platform technology at a worldwide level is the chemical modification, development, and manufacturing of state-of-the-art pharmaceuticals and medical devices based on hyaluronan covering multiple therapeutic categories including joint care, advanced wound care, and aesthetic medicine.

Helping people stay healthy is Fidia's corporate commitment.  For more information, visit www.fidiapharma.com.

(1)  Data on File, Fidia Farmaceutici S.p.A.
BP.F.H.035  911


'/>"/>
SOURCE Fidia Farmaceutici S.p.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
2. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
3. Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
5. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
10. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, ... provides technology solutions to improve the clinical effectiveness ... results for the first quarter ended March 31, ... products enable our customers to identify when preventive ... intervene before events like heart attacks or strokes ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
(Date:5/4/2017)... Inc. (" Fortuna "), a private, clinical-stage biotech company, ... for embryonic and fetal stem cells by using direct reprogramming ... announced today the launch of its Scientific Advisory ... Father Kevin FitzGerald , S.J., PhD; Col. (R) ... , PhD. "We are excited and honored to ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... ... and Clinical Integration company, announced today that its iClinic V12.2 solution has achieved ... Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize team-based care with ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability ... Policy Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price ... Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, ...
(Date:5/23/2017)... ... May 23, 2017 , ... By all indications, and due ... County. While officials call for diligence, asking homeowners to scout for any open water ... concerns. Along with the annoying buzz of mosquitos is the buzz associated with potential ...
(Date:5/23/2017)... ... 2017 , ... Orbita’s Nathan Treloar will discuss the role of voice-powered healthcare ... Connected Health and IoT: Technology Innovators and Disruption , the workshop is part ... market research and consulting firm specializing in emerging consumer technology products and services. , ...
(Date:5/22/2017)... ... May 22, 2017 , ... The ... the scientific development, healthcare training and clinical application of medical infrared imaging, has ... to perform medical thermal imaging services. , The first new educational offering is ...
Breaking Medicine News(10 mins):